ChiCTR2500112337 版本V1.0 版本创建时间2025/11/12 16:26:11 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500112337 

最近更新日期:

Date of Last Refreshed on:

2025-11-12 16:25:53 

注册时间:

Date of Registration:

2025-11-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于融合感知技术与人工智能的左旋多巴负荷试验评测在帕金森综合征诊断应用的前瞻性临床研究

Public title:

A prospective clinical study on the evaluation of levodopa challenge test based on fusion sensing technology and artificial intelligence for the diagnosis of Parkinson's syndrome.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于融合感知技术与人工智能的左旋多巴负荷试验评测在帕金森综合征诊断应用的前瞻性临床研究

Scientific title:

A prospective clinical study on the evaluation of levodopa challenge test based on fusion sensing technology and artificial intelligence for the diagnosis of Parkinson's syndrome.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

马凌燕 

研究负责人:

冯涛 

Applicant:

Lingyan Ma 

Study leader:

Tao Feng 

申请注册联系人电话:

Applicant telephone:

+86 13520873987

研究负责人电话:

Study leader's
telephone:

+86 13911125339

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Jennifer_MLY@163.com

研究负责人电子邮件:

Study leader's E-mail:

happyft@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市丰台区花乡街道南四环西路119号

研究负责人通讯地址:

北京市丰台区南四环西路119号

Applicant address:

No. 119, South Fourth Ring West Road, Huaxiang Street, Fengtai District, Beijing

Study leader's address:

119 South Fourth Ring West Road, Fengtai District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京天坛医院

Applicant's institution:

Beijing Tiantan Hospital affiliated to Capital Medical University

研究负责人所在单位:

首都医科大学附属北京天坛医院

Affiliation of the Leader:

Beijing Tiantan Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2024-347-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京天坛医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Tiantan Hospital Affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-07 00:00:00

伦理委员会联系人:

梁晓珊

Contact Name of the ethic committee:

Liang XiaoShan

伦理委员会联系地址:

北京市丰台区南四环西路119号

Contact Address of the ethic committee:

119 South Fourth Ring West Road, Fengtai District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 59975692

伦理委员会联系人邮箱:

Contact email of the ethic committee:

liangxiaoshan127@126.com

研究实施负责(组长)单位:

首都医科大学附属北京天坛医院

Primary sponsor:

Beijing Tiantan Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市丰台区南四环西路119号

Primary sponsor's address:

119 South Fourth Ring West Road, Fengtai District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院

具体地址:

北京市丰台区南四环西路119号

Institution
hospital:

Beijing Tiantan Hospital, Capital Medical University

Address:

119 South Fourth Ring West Road, Fengtai District, Beijing

经费或物资来源:

深圳市臻络科技有限公司

Source(s) of funding:

GYENNO SCIENCE CO., LTD.

研究疾病:

帕金森病。  

Target disease:

Parkinson's disease.

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

针对新发、未规范服用左旋多巴制剂、病程小于3年的帕金森综合征患者,采用传统运动范式与新型运动范式相结合,评估受试者进行左旋多巴冲击试验用药前后的运动症状,进行定期随访并修正诊断。整个过程中应用机器视觉、可穿戴等融合感知技术对运动症状进行检测、识别与捕捉,进而利用特定人工智能模型进行诊断,探索其与经典诊断方法的性能差异。  

Objectives of Study:

For patients with newly diagnosed Parkinsonian syndrome who have not undergone standardized levodopa treatment and have a disease duration of less than 3 years, this study combines traditional and novel motor paradigms to assess motor symptoms before and after levodopa challenge tests. Through periodic follow-ups and diagnostic adjustments, the research employs integrated sensing technologies including machine vision and wearable devices to detect, recognize, and capture motor manifestations. Specialized artificial intelligence models are subsequently utilized for diagnostic purposes, aiming to explore performance differences compared to classical diagnostic methods throughout the process.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 基于2015国际运动障碍协会(MDS)帕金森病诊断标准诊断为确诊的帕金森综合征患者;
2. 新发、未规范服用左旋多巴制剂、病程小于3年;
3. 受试者18-80岁(包含边界值),性别不限;
4. 同意接受研究相关的检查评估并签署知情同意书。

Inclusion criteria

1. Patients diagnosed with clinically established Parkinsonian syndrome according to the 2015 International Movement Disorder Society (MDS) diagnostic criteria for Parkinson's disease;
2. Newly diagnosed (disease duration <3 years) with no prior standardized levodopa therapy;
3. Aged 18–80 years (inclusive), regardless of gender;
4. Willing to undergo study-related evaluations and provide written informed consent.

排除标准:

1. 严重认知功能障碍,无法完成评估范式;
2. 无法耐受左旋多巴冲击试验;
3. 伴有重要的器官(心、肺、肝、肾等)衰竭、恶性肿瘤、病情不稳定及其他严重内科疾病者;
4. 有严重的行为问题或精神障碍者;
5. 无法签署知情同意;
6. 研究者认为其不适合参与本研究的其他情况。

Exclusion criteria:

1. Severe cognitive impairment making assessment difficult;
2. Unable to undergo levodopa challenge test;
3. Severe organ failure (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions, or other serious medical issues;
4. Severe behavioral or mental disorders;
5. Unable to consent to the study;
6. Other situations where the investigator deems participation unsuitable.

研究实施时间:

Study execute time:

From 2024-08-01 00:00:00 To 2029-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-31 00:00:00 To 2029-12-31 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

多种诊断标准下的多专家综合诊断结论

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Comprehensive Diagnostic Conclusion from Multiple Experts Based on Various Diagnostic Criteria.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

基于包含创新动作范式、融合感知和人工智能的定量评估方法,结合左旋多巴冲击试验

Index test:

Based on a quantitative evaluation method that incorporates innovative action paradigms, fusion perception, and artificial intelligence, combined with the levodopa shock test

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

帕金森病(PD)

例数:

Sample size:

1200

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Parkinson's disease (PD)

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

none

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Tiantan Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

青岛大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Qingdao University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆市 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属瑞金医院 

单位级别:

三级甲等 

Institution
hospital:

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

吉林省 

市(区县):

 

Country:

China

Province:

Jilin

City:

单位(医院):

吉林大学中日联谊医院 

单位级别:

三级甲等 

Institution
hospital:

China-Japan Union Hospital of Jilin University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

武汉大学人民医院 

单位级别:

三级甲等 

Institution
hospital:

Renmin Hospital of Wuhan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

徐州医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Xuzhou Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Fujian Medical University Union Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江西省 

市(区县):

 

Country:

China

Province:

Jiangxi

City:

单位(医院):

南昌大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Nanchang University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省人民医院(广东省医学科学院) 

单位级别:

三级甲等 

Institution
hospital:

Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

空军军医大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

Air Force Medical University Xijing Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

苏州大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Soochow University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽省 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

皖南医学院弋矶山医院 

单位级别:

三级甲等 

Institution
hospital:

Yijishan Hospital of Wannan Medical college

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东大学齐鲁医院 

单位级别:

三级甲等 

Institution
hospital:

Qilu Hospital of Shandong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

吉林省 

市(区县):

 

Country:

China

Province:

Jilin

City:

单位(医院):

吉林大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Jilin University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

天津市 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Medical University General Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽省 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

安徽医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Anhui Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

天津市 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市环湖医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Huanhu Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南省 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

云南省第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Yunnan First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京脑科医院 

单位级别:

三级甲等 

Institution
hospital:

Nanjing Brain Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

辽宁省 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

大连医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Dalian Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

新疆维吾尔自治区 

市(区县):

 

Country:

China

Province:

Xinjiang Uygur Autonomous Region

City:

单位(医院):

新疆医科大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Xinjiang Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

华中科技大学同济医学院附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

鉴别诊断的阳性预测值

指标类型:

次要指标

Outcome:

Positive Predictive Value for differential diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

对帕金森病及其他帕金森综合征进行鉴别诊断,在所有测试结果为阳性的个体中,真正患有疾病的比例。

Measure time point of outcome:

Measure method:

In the differential diagnosis of Parkinson's disease and other Parkinsonian syndromes, it refers to the proportion of individuals who truly have the disease among all those testing positive.

指标中文名:

早期诊断的阴性预测值

指标类型:

主要指标

Outcome:

Negative Predictive Value for early diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期诊断的特异性

指标类型:

主要指标

Outcome:

Specificity for early diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期诊断的准确率

指标类型:

主要指标

Outcome:

Accuracy for early diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鉴别诊断的阴性预测值

指标类型:

次要指标

Outcome:

Negative Predictive Value for differential diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鉴别诊断的准确率

指标类型:

次要指标

Outcome:

Accuracy for differential diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鉴别诊断的特异性

指标类型:

次要指标

Outcome:

Specificity for differential diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期诊断的灵敏度

指标类型:

主要指标

Outcome:

Sensitivity for early diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鉴别诊断的灵敏度

指标类型:

次要指标

Outcome:

Sensitivity for differential diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期诊断的阳性预测值

指标类型:

主要指标

Outcome:

Positive Predictive Value for early diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期诊断的诊断效能

指标类型:

主要指标

Outcome:

Diagnostic Odds Ratio for early diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鉴别诊断的诊断效能

指标类型:

次要指标

Outcome:

Diagnostic Odds Ratio for differential diagnosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后,在公开发表的学术论文中公布,可与Jennifer_MLY@163.com联系获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Upon completion of the study, the findings will be published in peer-reviewed academic journals. For access, please contact Jennifer_MLY@163.com.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过EDC采集和管理数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data will be collected and managed through EDC.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-11-12 16:25:53